This is consistent with our study where patients with HER2 IHC 3+ benefited from adjuvant anti-HER2 therapy in terms of prolonged BCSS and DMFS compared to HER2 IHC 2 + /Amplified BC patients. The gene discussed is ERBB2; the disease is breast cancer.